Prognosismodifying therapy in patients with CAD: how to optimize treatment?

Authors: Khanyukov A.A., Professor, Doctor of Medical Sciences, Head of the Department of Internal Medicine,

Aspects of the use of metabolic therapy in patients with cognitive impairment in post-COVID syndrome

Authors: V. O. Kholin, K. M. Poletaeva, A. A. Tikhonenko, N. Yu. D. F. Chebotareva

Ripronate is a new drug meldonium from a European manufacturer

The pathogenesis of each disease is based on one or another typical pathological process: hypoxia,

Improving the effectiveness of treatment for patients with diabetic retinopathy

Authors: Skrypnyk R.1, Skrypnychenko I.1, Dziuba N.2 1 Bogomolets National Medical University, Kyiv, Ukraine 2